Wednesday, April 21, 2021 11:42:08 AM
US Marijuana BOOM is gonna send Greater Cannabis to MOON!! Those who've done actual due diligence know that.
GCAN has recently relisted to OTCQB. Investors can find current financial disclosure and Real-Time Level 2 quotes of the Company on www.otcmarkets.com.
Cannabis stock GCAN has only 478.63 million shares outstanding including 9.72 million restricted shares. With this super low OS and such a hottest sector, PPS @ $0.25..$0.50..$1..$2++??, anything is possible.
https://www.otcmarkets.com/stock/GCAN/security
Shorts are screwed-up here. Huge shorts squeeze is imminent. Total Naked Shorted Volume is 38.93 Million with an average shorted volume of 1.95 Million. Shorts are gonna be roasted and burnt.
https://marketwirenews.com/stock/gcan/short/
Remember, this kind of opportunity comes once in a lifetime. Folks, act prudently and be financially solvent at this very very difficult time.
Let's go GCAN to $1++ !!
Know What You Own
GCANRx Announces Collaboration with Renowned Cannabis Research Lab
BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTCQB: GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products is proud to announce a collaboration with Israel-based cannabis lab, Phytor LTD, a leader in the research and development of plant-based therapeutics.
Under this collaboration, the companies will develop and commercialize novel therapeutics for dermatological, chronic ailments and other conditions that have been notoriously difficult to treat using conventional therapies. The focus will be on cannabinoid and botanical-based wellness solutions, products and therapies that have consumer or commercial use cases.
Phytor is led by Dr. Yehoshua Maor, a pharmacologist, toxicologist and cannabis expert who completed his graduate studies at the Hebrew University under the supervision of renowned professor, Dr. Raphael Mechoulam, one of the most acclaimed cannabis researchers, and known throughout the world as the “Father of Cannabis Research''. Dr. Maor’s research focused on both chemistry and biology of cannabinoids, which led him to gain immense knowledge in the bioactivity, pharmacokinetics and synthesis of cannabinoids, and an advanced understanding of their relevant therapeutic potential. As a graduate student he received awards for outstanding scientific presentations at the International Cannabis Research Society (ICRS). He was also a postdoctoral fellow of experimental medicine at the Harvard Institutes of Medicine before accepting a lead position at the Hebrew University Center of Excellence in Agriculture and Environmental Health. Under his direction, Phytor has become a world renowned cannabis R&D facility with an established team of multidisciplinary PhDs skilled in advanced science and research of pharmacological, agricultural and genetic characteristics of cannabinoids.
“We are delighted to be joining forces with GCANRx to collaborate on cutting edge cannabinoid and botanical-based therapies. Many of today’s conventional treatments require hormone based actives that cannot be used long term and have a host of side effects. Our focus is on developing natural, botanical compounds that are similar in their properties to existing pharmaceutical standards of care, but which can provide natural, rapid and sustained relief to patients who have long sought safer and more effective treatments”, stated Dr. Maor.
GCANRx CEO, Aitan Zacharin, had this to say, “We are excited to be forming this collaborative partnership with Phytor, and harnessing their tremendous knowledge, resources and industry expertise. Dr. Maor and his team have a stellar record of staying ahead of the emerging science on plant-based therapeutics, particularly those involving cannabinoids, and have demonstrated their expertise in isolating active compounds of plant origin and developing them into highly valuable therapeutic agents that improve patient and consumers’ lives.” Mr. Zacharin concluded, “As we begin to explore combining our delivery platform with Phytor’s development capabilities we will be looking for low hanging opportunities that we can tackle to broaden the applicability of our technology.”
https://ca.finance.yahoo.com/news/gcanrx-announces-collaboration-renowned-cannabis-131200335.html
Greater Cannabis Just Presented at the Benzinga Cannabis Capital Conference!
https://ca.finance.yahoo.com/news/greater-cannabis-present-benzinga-cannabis-145300583.html
Greater Cannabis Company Announces Retirement of Remaining Convertible Debt - MEANS ZERO DILUTION!!
BALTIMORE, MD, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The Greater Cannabis Company (GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products today announced the retirement of $1.2million in convertible notes inclusive of principal and accrued interest, simplifying the Company's capital structure as it positions itself for growth.
"The elimination of variable rate convertible notes has strengthened our position and simplified our capital structure as we look towards the future for the Company’s growth," commented Aitan Zacharin, CEO of Greater Cannabis. "We are focused on continuing to expand our product portfolio, distribution both domestically and abroad, as well as advancement of clinical research opportunities in cannabinoid therapeutics. The retirement of our debt is an important step for the Company as we continue to position ourselves as an innovator in a rebounding sector that has quickly become center stage once again.”
https://ca.finance.yahoo.com/news/greater-cannabis-company-announces-retirement-135700633.html
The Greater Cannabis Company Announces Launch of Bob Ross Beauty and Cosmetics Products
https://ca.finance.yahoo.com/news/greater-cannabis-company-announces-launch-151000151.html
Recent GCAN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:58:24 PM
- Form PRER14C - Information statements • Edgar (US Regulatory) • 02/26/2024 09:09:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 08:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 04:03:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 10:11:59 AM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM